<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01357512</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIAMRI</org_study_id>
    <nct_id>NCT01357512</nct_id>
  </id_info>
  <brief_title>Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer</brief_title>
  <official_title>Evaluation of Diagnostic Value of 3-T MRI in Suspected Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the usefulness of 3-T magnetic resonance imaging
      (MRI) in the evaluation of suspected prostate cancer. Men with suspected prostate cancer
      based on serum prostate-specific antigen antigen (PSA) value are included. Men are randomized
      to pre-biopsy MRI or no MRI groups in ratio 1:1. Standard transrectal ultrasound guided
      biopsies will be taken in addition to extra biopsies from lesions suspicious based on MRI
      evaluation. Hypothesis is that more prostate cancers will be found after MRI evaluation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Prostate Cancer Diagnoses in MRI and no MRI Groups</measure>
    <time_frame>at the end of the study (up to 1 year)</time_frame>
    <description>The number of patients with confirmed prostate cancer among men with MRI performed before biopsies are compared to the number of patients with prostate cancer confirmed in prostate biopsies without MRI. The number patients with prostate cancer are counted as total from cancers detected in random biopsies and in biopsies targeted based on suspicious MRI findings in MRI group, and from random biopsies in no MRI group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Positive Biopsies in MRI and no MRI Groups</measure>
    <time_frame>at the end of the study (up to 1 year)</time_frame>
    <description>The number of biopsies with histology confirming prostate cancer are compared between MRI and no MRI groups. This measure will clarify if prostate cancer can be diagnosed more accurately, i.e. more biopsies with confirmed prostate cancer, after MRI. Ten or 12 biopsies will be taken from prostates below 30 grams, or equal or above 30 grams, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Clinically Significant Prostate Cancers Detected in MRI and no MRI Groups</measure>
    <time_frame>at the end of the study (up to 1 year)</time_frame>
    <description>Number of clinically significant prostate cancers detected with and without MRI. Clinically significant prostate cancer is determined by the Gleason grading and be the number of cancer-positive biopsy cores.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>MRI done</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with MRI prior prostate biopsies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no MRI</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No MRI before prostate biopsies</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>magnetic resonance imaging, Siemens</intervention_name>
    <description>Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device</description>
    <arm_group_label>MRI done</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Suspected prostate cancer based on PSA value (total PSA 2,5-10 ng/ml and PSA free to
             total ratio &lt;=0.15, or total PSA 10-20 ng/ml)

          -  PSA and serum creatinine measurement less than 60 days before transrectal
             ultrasound-guided prostate biopsies

          -  No evidence of PSA increase by non-cancerous factors (catheterization, bladder stones,
             urinary tract infection including bacterial prostatitis)

        Exclusion Criteria:

          -  Previous prostate biopsies

          -  Previous prostate surgery

          -  Contraindication for MRI (such as pacemaker or inner ear implant)

          -  Claustrophobia

          -  Estimated glomerular filtration rate (eGFR) &lt;40 ml/min

          -  Suspected clinical T3-T4 prostate cancer based on digital rectal examination

          -  Contraindication for transrectal ultrasound-guided prostate biopsies

          -  body mass index &gt;30
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markku Vaarala, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>May 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2011</study_first_posted>
  <results_first_submitted>June 1, 2015</results_first_submitted>
  <results_first_submitted_qc>June 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2015</results_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oulu</investigator_affiliation>
    <investigator_full_name>Markku Vaarala, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>prostate cancer diagnosis</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>prostate biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MRI Done</title>
          <description>Subjects with MRI prior prostate biopsies
magnetic resonance imaging, Siemens: Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device</description>
        </group>
        <group group_id="P2">
          <title>no MRI</title>
          <description>No MRI before prostate biopsies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Population with protocol violations excluded</population>
      <group_list>
        <group group_id="B1">
          <title>MRI Done</title>
          <description>Subjects with MRI prior prostate biopsies
magnetic resonance imaging, Siemens: Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device</description>
        </group>
        <group group_id="B2">
          <title>no MRI</title>
          <description>No MRI before prostate biopsies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="113"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="60" upper_limit="66"/>
                    <measurement group_id="B2" value="62" lower_limit="56" upper_limit="67"/>
                    <measurement group_id="B3" value="62" lower_limit="58" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum prostate-specific antigen level</title>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.1" lower_limit="4.2" upper_limit="9.9"/>
                    <measurement group_id="B2" value="6.2" lower_limit="4.0" upper_limit="10.7"/>
                    <measurement group_id="B3" value="6.1" lower_limit="4.1" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Prostate Cancer Diagnoses in MRI and no MRI Groups</title>
        <description>The number of patients with confirmed prostate cancer among men with MRI performed before biopsies are compared to the number of patients with prostate cancer confirmed in prostate biopsies without MRI. The number patients with prostate cancer are counted as total from cancers detected in random biopsies and in biopsies targeted based on suspicious MRI findings in MRI group, and from random biopsies in no MRI group.</description>
        <time_frame>at the end of the study (up to 1 year)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MRI Done</title>
            <description>Subjects with MRI prior prostate biopsies
magnetic resonance imaging, Siemens: Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device</description>
          </group>
          <group group_id="O2">
            <title>no MRI</title>
            <description>No MRI before prostate biopsies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Prostate Cancer Diagnoses in MRI and no MRI Groups</title>
          <description>The number of patients with confirmed prostate cancer among men with MRI performed before biopsies are compared to the number of patients with prostate cancer confirmed in prostate biopsies without MRI. The number patients with prostate cancer are counted as total from cancers detected in random biopsies and in biopsies targeted based on suspicious MRI findings in MRI group, and from random biopsies in no MRI group.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Positive Biopsies in MRI and no MRI Groups</title>
        <description>The number of biopsies with histology confirming prostate cancer are compared between MRI and no MRI groups. This measure will clarify if prostate cancer can be diagnosed more accurately, i.e. more biopsies with confirmed prostate cancer, after MRI. Ten or 12 biopsies will be taken from prostates below 30 grams, or equal or above 30 grams, respectively.</description>
        <time_frame>at the end of the study (up to 1 year)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MRI Done</title>
            <description>Subjects with MRI prior prostate biopsies
magnetic resonance imaging, Siemens: Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device</description>
          </group>
          <group group_id="O2">
            <title>no MRI</title>
            <description>No MRI before prostate biopsies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Positive Biopsies in MRI and no MRI Groups</title>
          <description>The number of biopsies with histology confirming prostate cancer are compared between MRI and no MRI groups. This measure will clarify if prostate cancer can be diagnosed more accurately, i.e. more biopsies with confirmed prostate cancer, after MRI. Ten or 12 biopsies will be taken from prostates below 30 grams, or equal or above 30 grams, respectively.</description>
          <units>number of cancer-positive biopsy cores</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.75" upper_limit="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Clinically Significant Prostate Cancers Detected in MRI and no MRI Groups</title>
        <description>Number of clinically significant prostate cancers detected with and without MRI. Clinically significant prostate cancer is determined by the Gleason grading and be the number of cancer-positive biopsy cores.</description>
        <time_frame>at the end of the study (up to 1 year)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MRI Done</title>
          <description>Subjects with MRI prior prostate biopsies
magnetic resonance imaging, Siemens: Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device</description>
        </group>
        <group group_id="E2">
          <title>no MRI</title>
          <description>No MRI before prostate biopsies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>collapse</sub_title>
                <description>Collapse after prostate biopsy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief urologist Markku Vaarala</name_or_title>
      <organization>Oulu University Hospital and Univeristy of Oulu</organization>
      <phone>+3588315 ext 2840</phone>
      <email>markku.vaarala@oulu.fi</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

